Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=4d1caa7b-8398-4536-9cb9-89e59e52911c
Date 5/13/2014
Company Name Lysosomal Therapeutics
Mailing Address 19 Blackstone Street Cambridge, MA 02139 USA
Company Description LTI’s unique approach to discovering new drugs for neurodegenerative diseases is based on research performed in the lab of Dr. Dimitri Krainc, one of the company’s founders, at Massachusetts General Hospital (MGH), a founding member of Partners HealthCare and an affiliate of Harvard Medical School.
Proceeds Purposes This seed funding will be instrumental in enabling LTI to progress its GCase program through the lead-generation process and in setting us up for preclinical development.